Chlamydia pneumoniae-mediated inflammation in atherosclerosis: a meta-analysis. by Filardo, Simone et al.
Review Article
Chlamydia pneumoniae-Mediated Inflammation in
Atherosclerosis: A Meta-Analysis
Simone Filardo,1 Marisa Di Pietro,1 Alessio Farcomeni,2
Giovanna Schiavoni,1 and Rosa Sessa1
1Section of Microbiology, Department of Public Health and Infectious Diseases, “Sapienza” University, Rome, Italy
2Section of Statistic, Department of Public Health and Infectious Diseases, “Sapienza” University, Rome, Italy
Correspondence should be addressed to Rosa Sessa; rosa.sessa@uniroma1.it
Received 8 May 2015; Accepted 15 July 2015
Academic Editor: Uma Nagarajan
Copyright © 2015 Simone Filardo et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Several studies have attempted to relate the C. pneumoniae-mediated inflammatory state with atherosclerotic cardiovascular
diseases, providing inconsistent results. Therefore, we performed a meta-analysis to clarify whether C. pneumoniaemay contribute
to the pathogenesis of atherosclerosis by enhancing inflammation. 12 case-control, 6 cross-sectional, and 7 prospective studies
with a total of 10,176 patients have been included in this meta-analysis. Odds Ratio (OR) with a 95% confidence interval was
used to assess the seroprevalence of C. pneumoniae and differences between levels of inflammatory markers were assessed by
standard mean differences. Publication bias was performed to ensure the statistical power. hsCRP, fibrinogen, interleukin- (IL-)
6, TNF-𝛼, and IFN-𝛾 showed a significant increase in patients with atherosclerosis compared to healthy controls (𝑃 < 0.05), along
with a higher seroprevalence of C. pneumoniae (OR of 3.11, 95% CI: 2.88–3.36, 𝑃 < 0.001). More interestingly, hsCRP, IL-6, and
fibrinogen levels were significantly higher in C. pneumoniae IgA seropositive compared to seronegative atherosclerotic patients
(𝑃 < 0.0001). In conclusion, the present meta-analysis suggests that C. pneumoniae infection may contribute to atherosclerotic
cardiovascular diseases by enhancing the inflammatory state, and, in particular, seropositivity to C. pneumoniae IgA, together with
hsCRP, fibrinogen, and IL-6, may be predictive of atherosclerotic cardiovascular risk.
1. Introduction
Atherosclerosis, a chronic inflammatory disease of multifac-
torial aetiology, typically begins with endothelial dysfunc-
tion followed by low density lipoprotein (LDL) infiltration
of the arterial intima, mononuclear cell recruitment into
vascular wall, and the differentiation of macrophages in
foam cells [1, 2]. Macrophages and foam cells, within the
evolving atherosclerotic lesion, secrete various proinflam-
matory cytokines, such as interleukin- (IL-) 6, interferon-
(IFN-) 𝛾, tumor necrosis factor- (TNF-) 𝛼, and chemokines,
including intercellular adhesion molecule- (ICAM-) 1 and
vascular cell adhesion molecule- (VCAM-) 1. In response
to proinflammatory cytokines, endothelial cells express high
levels of leukocyte adhesion molecules on their surface,
leading to further mononuclear cell recruitment and, hence,
to a chronic inflammatory state [3, 4]. As a result, the
formation, progression, and destabilisation of atherosclerotic
plaque occur, leading to cardiovascular diseases, a major
public health problem in developed countries, accounting for
one-third of all deaths worldwide [5].
In the last decades, several infectious agents have been
related to the pathogenesis of atherosclerotic cardiovascular
diseases, and current opinion is that the most implicated
pathogen is Chlamydia pneumoniae, an obligate intracellular
microorganism, known as being responsible for respiratory
tract infections [6, 7].
The association between C. pneumoniae and atheroscle-
rotic cardiovascular diseases has been well documented
by seroepidemiological studies [8–12], direct detection of
microorganism within atherosclerotic plaque [13–17], and in
vivo studies showing an atherosclerotic lesion exacerbation
following C. pneumoniae inoculation of hyperlipidemic ani-
mal models [18–23].
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C. pneumoniae is presumed to play a role in atheroscle-
rotic cardiovascular diseases for its ability to systemati-
cally disseminate from the lung through peripheral blood
mononuclear cells and to localise in extrapulmonary tissues,
such as the vascular wall [24–28]. Once being inside the
vascular tissue, C. pneumoniae has been shown to act directly
on the cells involved in atherosclerotic process, contributing
to endothelial dysfunction, foam cell formation, vascular
smoothmuscle cell (VSMC) proliferation andmigration, and
platelet aggregation [29–33]. Indeed, C. pneumoniae is able
to multiply within macrophages, platelets, endothelial cells,
and VSMCs and to induce the elicitation of proinflammatory
cytokines, such as IL-6, IFN-𝛾, and TNF-𝛼, and adhesion
molecules, such as ICAM-1 and VCAM-1, as well as reactive
oxygen species, thus contributing to the chronic inflamma-
tory state responsible for the initiation, progression, and
destabilisation of atherosclerotic plaque [34–40].
Specifically, C. pneumoniae persistent form seems to
be responsible for chronic infection and, hence, for the
inflammatory process underlying atherosclerosis, since it is
able to endure for a long time inside host cells [41, 42].
In addition to the direct effect on vascular cells, previously
described, C. pneumoniae has also shown to contribute to
the systemic inflammation involved in the pathogenesis of
atherosclerotic cardiovascular diseases, as evidenced by high
levels of IL-6 and high sensitivity c-reactive protein (hsCRP)
[7, 43].
Given the central role of inflammation in the atheroscle-
rotic process and the inflammatory effects of C. pneumoniae,
several studies have attempted to relate the C. pneumoniae-
mediated inflammatory state with atherosclerotic cardiovas-
cular diseases, providing inconsistent results.
We performed, therefore, a meta-analysis to clarify
whether C. pneumoniae may contribute to the pathogenesis
of atherosclerotic cardiovascular diseases by the means of
enhanced inflammatory state.
2. Materials and Methods
2.1. Search Strategy. We performed a systematic search of
all articles in journals indexed on the electronic databases
PubMed and Scopus up to December 2014. The search
terms used were “chlamydia pneumoniae” or “chlamydophila
pneumoniae,” “inflammatory markers” or “inflammation,”
“atherosclerosis,” and “cardiovascular disease.”The reference
lists of reviews and retrieved articles were hand-searched
simultaneously. When more than one of the same patient
population was included in several publications, only the
most recent or complete study was included in this meta-
analysis.
2.2. Inclusion and Exclusion Criteria. The inclusion criteria
in this meta-analysis were as follows: (i) studies comparing
atherosclerotic patients with healthy subjects (control group)
in relation to the seropositivity to C. pneumoniae IgG or IgA,
(ii) studies comparing atherosclerotic patients in relation to
the seropositivity to C. pneumoniae IgG or IgA, and (iii)
studies analysing the levels of inflammatory markers.
Case reports, reviews, letters, and studies which did not
present their results in a correct and/or explicit manner, ani-
mal studies, and studies where the control groups were made
up of patients with other chronic inflammatory disorders
were excluded from ourmeta-analysis. We did not define any
minimum number of patients to include a study in our meta-
analysis.
2.3. Data Extraction. Information was carefully extracted
from all eligible publications independently by two authors
according to the inclusion and exclusion criteria listed above.
Disagreement was resolved by discussion between the two
authors. The following data were collected from each study:
first author’s surname, year of publication, study design,
type of cases, type of controls, total numbers of cases and
controls, prevalence of traditional risk factors for CVD
(obesity, diabetes, smoking, dyslipidemia, and hypertension),
the prevalence of C. pneumoniae antibodies (IgA or IgG),
determined by microimmunofluorescence or ELISA, and the
levels of inflammatory markers (CRP, IL-6, fibrinogen, IFN-
𝛾, TNF-𝛼, ICAM-1, and VCAM-1).
Only inflammatory markers analysed by at least two
studies were included in our meta-analysis.
2.4. Statistical Analysis. Differences between groups were
assessed by means of differences in averages and standard
deviations of the difference, as markers assessed were all
continuous. Standard errors were computed after a normal
approximation. Pooled effects were computed by means of
a meta-analysis. The meta-analysis conducted was strictly
under heterogeneity among studies, by means of a hierarchi-
cal Bayesian model. Effect sizes were assumed to be normally
distributed. Each study effect was assumed to arise from a
Gaussian centered on a study-specific effect and the extracted
standard error, inflated by 25% to obtain a conservative state-
ment. The study-specific effect was assumed to be Gaussian,
centered on an unknown pooled effect, which is the main
object of interest. An informative prior was used for the
variance of the pooled effect, as an inverse Gamma centered
on an estimator obtained with a moment-based approach
(inflated by 25% to obtain a conservative statement). We also
estimated posterior probabilities of no difference (𝑃).𝑃 of less
than 0.05 was considered as statistically significant. Potential
publication bias was estimated using Egger’s linear regression
test and funnel plots. Sensitivity analyses were assessed by
deleting each study; in all cases, pooled estimates were very
stable.
All data were collected usingMicrosoftOffice Excel 2007;
statistical analyses were performed using R software.
3. Results
3.1. Study Characteristics. 25 studies concerning the associ-
ation of C. pneumoniae and atherosclerosis through inflam-
mation met the inclusion criteria and comprised 12 case-
control, 6 cross-sectional, and 7 prospective studies [44–
68]. Overall, a total of 3633 cases and 2781 controls for the
case-control analysis, 1593 seropositive and 915 seronegative
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Table 1: Characteristics of the studies included in the case-control analysis.
First author Year Country Cases Number of cases Number of controls Study design Serology assay
Mundkur [68] 2012 India CAD 433 433 Prospective ELISA
Haider [67] 2011 India CAD 63 40 Cross-sectional ELISA
Jha [65] 2009 India CAD 192 192 Case-control ELISA
Jafarzadeh [64] 2008 Iran IHD 62 31 Case-control ELISA
Videm [63] 2007 Norway CAD 131 103 Case-control ELISA
Corrado [59] 2006 Italy A 456 212 Prospective ELISA
Kaperonis [61] 2006 Greece PAD 51 30 Cross-sectional ELISA
Romano Carratelli [62] 2006 Italy CAD 60 20 Case-control MIF
Adiloglu [57] 2005 Turkey A 88 91 Case-control ELISA
Lanza [55] 2004 Italy SA, cardiac SX 104 60 Case-control MIF
Linares-Palomino [56] 2004 Spain PAD 64 50 Case-control MIF
Biasucci [51] 2003 Italy UA, MI 259 100 Prospective MIF
Georges [53] 2003 Germany SA, UA 991 333 Case-control MIF
Bloemenkamp [49] 2002 Netherlands PAD 228 643 Case-control ELISA
Gattone [46] 2001 Italy MI 120 120 Case-control MIF
Anderson [44] 1998 USA CAD, MI 331 323 Case-control MIF
CAD, coronary artery disease; IHD, ischemic heart disease; A, atherosclerosis; PAD, peripheral artery disease; SA, stable angina; SX, syndrome X; UA, unstable
angina; MI, myocardial infarction.
Table 2: Characteristics of the studies included in the C. pneumoniae IgG and IgA analysis.
First author Year Country Cases Number of cases Number of controls Study design Serology assay
IgG
Nazmi [66] 2010 USA CAD 697 288 Cross-sectional MIF
Jitsuiki [60] 2006 Japan A 136 123 Cross-sectional ELISA
Adiloglu [57] 2005 Turkey A 227 17 Case-control ELISA
Zairis [54] 2003 Greece SA, UA 182 214 Prospective MIF
Altman [48] 2002 Argentina CAD 107 52 Case-control MIF
Schumacher [50] 2002 Norway CAD 119 74 Cross-sectional ELISA
Sander [47] 2001 Germany TIA, IS 125 147 Prospective MIF
IgA
Jha [65] 2009 India CAD 155 37 Case-control ELISA
Jitsuiki [60] 2006 Japan A 92 167 Cross-sectional ELISA
Schumacher [58] 2005 Norway CAD 63 130 Cross-sectional MIF
Gabriel [52] 2003 Sweden CAD 38 15 Prospective MIF
Zairis [54] 2003 Greece SA, UA 87 214 Prospective MIF
Toss [45] 1998 Sweden UA 93 163 Prospective MIF
CAD, coronary artery disease; A, atherosclerosis; SA, stable angina; UA, unstable angina; TIA, transient ischemic attack; IS, ischemic stroke.
patients for the C. pneumoniae IgG seropositive-seronegative
analysis, and 528 seropositive and 726 seronegative patients
for the C. pneumoniae IgA seropositive-seronegative analysis
were considered.One publication had apparently overlapping
cases with a second study, so that we extracted only the most
relevant data from both studies. Table 1 presents the main
characteristics of the included studies for the case-control
analysis, whereas Table 2 presents the main characteristics
of the included studies for the seropositive to seronegative
analysis according to C. pneumoniae IgG and IgA. Controls
were mainly healthy population andmatched for age and sex.
3.2. Meta-Analysis Results. Themeta-analysis was performed
on 16 studies (case-controls analysis, Table 1) comparing
atherosclerotic patients with healthy controls in relation to
the seropositivity to C. pneumoniae and levels of inflam-
matory markers (hsCRP, IL-6, fibrinogen, TNF-𝛼, IFN-𝛾,
ICAM-1, and VCAM-1) [44, 46, 49, 51, 53, 55–57, 59, 61–
65, 67, 68]. C. pneumoniae seroprevalence was 59.2% (95%
CI: 57.8–60.7) in cases and 31.2% (95% CI: 30.0–32.5) in
controls, with an OR of 3.11 (95% CI: 2.88–3.36, 𝑃 <
0.001). Concerning the inflammatory markers, hsCRP, IL-6,
fibrinogen, TNF-𝛼, and IFN-𝛾 showed a significant increase
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Table 3: Summary of SMDs and 95% CI of inflammatory marker levels in case-control analysis.
hsCRP
(mg/L)
IL-6
(ng/mL)
Fibrinogen
(mg/dL)
TNF-𝛼
(pg/mL)
IFN-𝛾
(pg/mL)
ICAM-1
(ng/mL)
VCAM-1
(ng/mL)
SMD 6.360 7.861 5.627 9.467 4.320 0.001 3.722
95% CI 5.76–6.96 7.40–8.32 0.65–10.60 6.45–12.49 2.32–6.32 −0.25–0.25 −1.46–8.90
𝑃 value <0.0001 <0.0001 0.00895 <0.0001 <0.0001 0.49628 0.06611
SMD, standard mean difference; CI, confidence interval.
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Figure 1: Forest plot of standardizedmean differences (SMDs) of individual studies and pooled SMDs for hsCRP (a), IL-6 (b), and fibrinogen
(c) in patients with atherosclerotic cardiovascular diseases and healthy controls.
in patients with atherosclerosis compared to health controls
(𝑃 < 0.05), whereas the adhesion molecules ICAM-1 and
VCAM-1 did not show any significant difference (𝑃 > 0.05)
(Table 3, Figure 1).
In addition, the meta-analysis was also performed on
studies comparing atherosclerotic patients seropositive to
C. pneumoniae IgG or IgA with seronegative patients.
Specifically, 7 studies comparing atherosclerotic patients
seropositive to C. pneumoniae IgG with seronegative patients
(C. pneumoniae IgG analysis, Table 2) [47, 48, 50, 54, 57,
60, 66] and 6 studies comparing atherosclerotic patients
seropositive to C. pneumoniae IgA with seronegative patients
(C. pneumoniae IgA analysis, Table 2) [45, 52, 54, 58, 60, 65],
both according to levels of inflammatorymarkers (hsCRP, IL-
6, fibrinogen, and IFN-𝛾), were evaluated.
For the C. pneumoniae IgG analysis, hsCRP, IL-6,
and fibrinogen levels were significantly higher in seropos-
itive compared to seronegative patients (𝑃 < 0.0001)
(Figure 2).
For the C. pneumoniae IgA analysis, hsCRP, IL-6, and
fibrinogen were markedly increased in seropositive patients
(𝑃 < 0.01), whereas IFN-𝛾 did not show any significant
difference between seropositive and seronegative patients
(𝑃 > 0.05) (Figure 3).
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Figure 2: Forest plot of standardizedmean differences (SMDs) of individual studies and pooled SMDs for hsCRP (a), IL-6 (b), and fibrinogen
(c) in C. pneumoniae IgG seropositive and seronegative patients with atherosclerotic cardiovascular diseases.
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Figure 3: Forest plot of standardizedmean differences (SMDs) of individual studies and pooled SMDs for hsCRP (a), IL-6 (b), and fibrinogen
(c) in C. pneumoniae IgA seropositive and seronegative patients with atherosclerotic cardiovascular diseases.
Results are independent of the main confounding factors
as the meta-analysis was computed under heterogeneity. We
also have verified that they could not form a relationship
with mean age and study proportions of males, patients with
diabetes, hypertension, obesity, smoking, dyslipidemia, and
risk factors for CVDs.
3.3. Publication Bias. Funnel plots and Egger’s test were
performed to assess publication bias. Publication bias was
detected only for meta-analysis of fibrinogen with IgA (𝑃 =
0.012). In particular no publication bias was detected for
hsCRP for IgA (𝑃 = 0.200), IgG (𝑃 = 0.890), and case-control
data (𝑃 = 0.122).
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4. Discussion
Atherosclerosis, precursor to cardiovascular diseases, is
recognised as a chronic inflammatory disease of large arteries,
involving cytokines, such as IFN-𝛾 and TNF-𝛼, adhesion
molecules, such as ICAM-1 and VCAM-1, and several plasma
inflammatory markers, such as hsCRP, IL-6, and fibrinogen
[2, 3]. The latter have been demonstrated to better correlate
with the chronic inflammation underlying atherosclerotic
cardiovascular diseases; in fact, IL-6, a proinflammatory
cytokine that plays a role in the instability of a vulnerable
plaque, and hsCRP, an acute-phase protein, appear to be
strong independent predictors of cardiovascular events [3].
Lastly, fibrinogen, a substrate leading to the generation of
thrombin, the end point of the hemostatic process, is involved
in the early formation and growth of the atherosclerotic
plaque [69].
As previously described, C. pneumoniae has been sug-
gested to contribute to the chronic inflammation underlying
the atherosclerotic process, as evidenced by elevated levels of
circulating inflammatory markers in atherosclerotic patients.
Gattone et al., in 2001, have suggested, for the first time, the
association of C. pneumoniae seropositivity and high hsCRP
levels, with increased risk of myocardial infarction [46].
Since then, other studies [47, 49, 50, 52, 57, 61, 64, 67] have
supported the relationship between C. pneumoniae infection
and atherogenesis through systemic inflammation. On the
other hand, some studies have failed to demonstrate such
association [44, 48, 55, 68], thus making it difficult to draw
conclusions.
To the best of our knowledge, our study is the first meta-
analysis to evaluate whether C. pneumoniae may contribute
to the pathogenesis of atherosclerotic cardiovascular diseases
by the means of enhanced inflammation, assessed by levels of
inflammatory markers.
The first result of our meta-analysis showed a significant
increase in hsCRP, fibrinogen, IL-6, TNF-𝛼, and IFN-𝛾
in atherosclerotic patients compared to healthy controls.
These data, together with the higher seroprevalence of C.
pneumoniae in atherosclerotic patients compared to healthy
controls (𝑃 < 0.001), suggest that C. pneumoniae infection
may contribute to the chronic inflammation underlying the
development and progression of atherosclerosis, even though
it is not possible to establish a causal relationship.
Consequently, in order to better define the contribution
ofC. pneumoniae on the inflammation underlying atheroscle-
rosis, we performed a further analysis on studies comparing
the levels of inflammatorymarkers in atherosclerotic patients
seropositive to C. pneumoniae IgG or IgA with seronegative
patients.
The more relevant data is that C. pneumoniae IgA
seropositivity was overall more strongly related to the inflam-
matory state than IgG seropositivity. Indeed, our results
showed an increase of inflammatory marker levels, such as
hsCRP, fibrinogen, and IL-6, in IgA seropositive patients.
Specifically, the standard mean differences of hsCRP, fibrino-
gen, and IL-6 were, respectively, 7.17, 7.79, and 1.37 times
higher in the IgA compared to the IgG analysis, thus show-
ing that seropositivity to C. pneumoniae IgA might better
correlate to a chronic inflammatory state in patients with
atherosclerosis. This is not particularly surprising since C.
pneumoniae IgA is considered a marker of chronic infection,
known to be involved in chronic disorders.
The main strength of our meta-analysis is the statistical
robustness of our data, since the results were not affected by
exclusion of any specific study from the pooled analysis.
However, our meta-analysis has potential limitations.
First, since multiple infectious agents, labeled as infectious
burden, rather than any single pathogen, have been shown
to contribute to the pathogenesis of atherosclerosis, the
inflammatory effect of C. pneumoniae might be overesti-
mated. Of note, in all the studies included in our meta-
analysis, data regarding other infectious agents were missing
or incomplete and, hence, we were not able to quantify their
influence on chronic inflammation. Second, potential bias
might be introduced in that not all the included studies
reported data concerning the confounding factors. Lastly,
two different diagnostic tests, along with different cutoffs,
were used for detecting C. pneumoniae seropositivity in the
included studies and, hence, may partly account for further
bias.
5. Conclusions
In conclusion, despite some limitations, our study suggests
that C. pneumoniae infection may contribute to atheroscle-
rotic cardiovascular diseases by enhancing the inflamma-
tory state, as demonstrated by increased levels of systemic
inflammatory markers. Furthermore, seropositivity to C.
pneumoniae IgA, together with hsCRP, fibrinogen, and IL-6,
may be predictive of atherosclerotic cardiovascular risk.
In the future, large scale, prospective, and well-designed
studies should be needed to deepen our knowledge concern-
ing the causative role of C. pneumoniae in inflammation in
atherosclerotic cardiovascular diseases.
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